What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring?

Best Practice and Research: Clinical Rheumatology

Volumn 19, Issue 6, 2005, Pages 951-964

  Briot, Karine ^a   Roux, Christian ^a  

^a Institut Cochin   (France)

Author keywords

Bone mineral density; Bone turnover markers; Fracture; Osteoporosis; Ultrasound

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; DEOXYPYRIDINOLINE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

BONE DENSITY; BONE MINERAL; BONE REMODELING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FOLLOW UP; FRAGILITY FRACTURE; HEALTH CARE COST; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; NON INVASIVE MEASUREMENT; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; VERTEBRA FRACTURE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DENSITOMETRY, X-RAY; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PATIENT CARE PLANNING; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 28644432050     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2005.06.004     Document Type: Review

References (67)

1. N.F. Ray J.K. Chan M. Thamer & L.J. Melton Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation Journal of Bone and Mineral Research 12 1997 24-35
2. B.L. Riggs & L.J. Melton 3rd The worldwide problem of osteoporosis: insights afforded by epidemiology Bone 17 1995 505S-511S
3. J.A. Kanis Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. WHO study group Osteoporosis International 4 1994 368-381
4. K.L. Stone D.G. Seeley L.Y. Lui et al. Osteoporotic Fractures Research Group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures Journal of Bone and Mineral Research 18 2003 1947-1954
5. D. Marshall O. Johnell & H. Wedel Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures British Medical Journal 312 1996 1254-1259
6. P. Dargent-Molina A.M. Schott D. Hans et al. Separate and combined value of bone mass and gait speed measurements in screening for hip fracture risk: Results from the EPIDOS study. Epidémiologie de l'ostéoporose Osteoporosis International 9 1999 188-192
7. J.A. Kanis Osteoporosis; diagnosis of osteoporosis and assessment of fracture risk Lancet 359 2002 1929-1936
8. S.R. Cummings D.M. Black M.C. Nevitt et al. Bone density at various sites for prediction of hip fractures. The study of osteoporotic fractures research group Lancet 341 1993 72-75
9. E.S. Siris Y.T. Chen T.A. Abbott et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures Archives of Internal Medicine 164 2004 1108-1112
10. D.M. Black S.R. Cummings D.B. Karpf et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1996 1535-1541
11. S.T. Harris N.B. Watts & H.K. Genant Effects of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial The Journal of the American Medical Association 282 1999 1344-1552
12. B. Ettinger D.M. Black B.H. Mitlak et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators The Journal of the American Medical Association 282 1999 637-645
13. R.M. Neer C.D. Arnaud J.R. Zanchetta et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis The New England Journal of Medicine 344 2001 1434-1441
14. P.J. Meunier C. Roux E. Seeman et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis The New England Journal of Medicine 350 2004 459-468
15. D.M. Black M. Steinbuch L. Palermo et al. An assessment tool for predicting fracture risk in postmenopausal women Osteoporosis International 12 2001 519-528
16. C.C. Gluer G. Blake Y. Lu et al. Accurate assessment of precision errors: How to measure the reproducibility of bone densitometry techniques Osteoporosis International 5 1995 262-270
17. P. Ravaud J.L. Reny B. Giraudeau et al. Smallest detectable difference in individual bone mineral density measurements Journal of Bone and Mineral Research 14 1999 1449-1456
18. M.C. Lodder W.F. Lems H.J. Ader et al. Reproducibility of bone mineral density measurement in daily practice Annals of the Rheumatic Diseases 63 2004 285-289
19. S.R. Cummings L. Palermo W. Browner et al. Monitoring osteoporosis therapy with bone densitometry. Misleading changes and regression to the mean The Journal of the American Medical Association 283 2000 1318-1321
20. U.A. Liberman S.R. Weiss J. Bröll et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group The New England Journal of Medicine 333 1995 1437-1443
21. H.G. Bone D. Hosking J.P. Devogelaer et al. Ten years'experience with alendronate for osteoporosis in postmenopausal women The New England Journal of Medicine 350 2004 1189-1199
22. S.T. Harris Bisphosphonates for the treatment of postmenopausal osteoporosis: Clinical studies of etidronate and alendronate Osteoporosis International 12 2002 S11-S16
23. P.D. Delmas N.H. Bjarnason B.H. Mitlak et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women The New England Journal of Medicine 337 1997 1641-1647
24. R. Marcus O. Wang J. Satterwhite & B. Mitlak The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis Journal of Bone and Mineral Research 18 2003 18-23
25. P.D. Delmas K.E. Ensrud J.D. Adachi et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial Journal of Clinical Endocrinology and Metabolism 87 2002 3609-3617
26. N.B. Watts C. Cooper R. Linday et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate Journal of Clinical Densitometry 7 2004 255-261
27. Z. Li M.P. Meredith & M.S. Hoseyni A method to assess the proportion of treatment effect explained by a surrogate end-point Statistics in Medicine 112 2001 281-289
28. S.R. Cummings D.B. Karpf F. Harris et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs The American Journal of Medicine 112 2002 281-289
29. S. Sarkar B.H. Mitlak M. Wong et al. Relationship between bone mineral density and incident vertebral fracture risk raloxifène therapy Journal of Bone and Mineral Research 17 2002 1-10
30. M.C. Hochberg S. Greenspan R.D. Wasnich et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents Journal of Clinical Endocrinology and Metabolism 87 2002 1586-1592
31. C.C. Glüer S.R. Cummings D.C. Bauer et al. Association of recent fractures with quantitative US findings Radiology 199 1996 25-32
32. D. Hans M.E. Arlot A.M. Schott et al. Do ultrasound measurements on the os calcis reflect more the microarchitecture than the bone mass? A two-dimensional histomorphometric study Bone 16 1995 295-300
33. D.T. Baran Quantitative ultrasound: A technique to target women with low bone mass for preventive therapy The American Journal of Medicine 98 1995 48S-51S
34. M.L. Frost G.M. Blake & I. Foelman Can the WHO criteria for diagnosing osteoporosis be applied to calcaneal quantitative ultrasound? Osteoporosis International 11 2000 321-330
35. K.M. Knapp G.M. Blake T.D. Spector et al. Can the WHO definition of osteoporosis be applied to multi-site axial transmission quantitative ultrasound? Osteoporosis International 15 2004 367-374
36. C. Cepollaro S. Gonnelli C. Pondrelli et al. The combined use of ultrasound and densitometry in the prediction of vertebral fracture The British Journal of Radiology 70 1997 691-696
37. D.C. Bauer C.C. Gluer H.K. Genant et al. Quantitative ultrasound and vertebral fracture in postmenopausal women. Fracture intervention trial research group Journal of Bone and Mineral Research 10 1995 353-358
38. P. Ross C. Huang J. Davis et al. Predicting vertebral deformity using bone densitometry at various skeletal sites and calcaneus ultrasound Bone 16 1995 325-332
39. C.C. Glüer R. Eastell D.M. Reid et al. Association of five quantitative ultrasound devices and bone densitometry with osteoporotic vertebral fractures in population-based sample: The OPUS study Journal of Bone and Mineral Research 19 2004 782-793
40. C. Roux B. Fournier P. Laugier et al. Broadband ultrasound attenuation imaging: A new imaging method in osteoporosis Journal of Bone and Mineral Research 11 1996 1112-1118
41. D. Hans P. Dargent-Molina A.M. Schott et al. Ultrasonographic heel measurements to predict hip fracture in erderly women: The EPIDOS prospective study Lancet 348 1996 511-514
42. D.C. Bauer C.C. Glüer J.A. Cauley et al. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women: A prospective study Archives of Internal Medicine 157 1997 629-634
43. J. Huopio H. Kroger R. Honkanen et al. Calcaneal ultrasound predicts early postmenopausal fractures as well as axial BMD. A prospective study of 422 women Osteoporosis International 15 2004 190-195
44. C.F. Njeh D. Hans et al. J. Li Comparison of six calcaneal quantitative ultrasound devices: Precision et and hip fracture discrimination Osteoporosis International 11 2000 1051-1062
45. M.A. Krieg J. Cornuz C. Cruffieux et al. Comparison of three bone ultrasounds for the discrimination of subjects with and without osteoporotic fractures among 7562 elderly women Journal of Bone and Mineral Research 18 2003 1261-1266
46. C. Wuster C. Albanese D. De Aloysio et al. Phalangeal osteosonogrammetry study: Age-related changes, diagnostic sensitivity, and discrimination power. The Phalangeal osteosonogrammetry study group Journal of Bone and Mineral Research 12 2000 1280-1288
47. P.L. Van Daele H. Burger C.E. De Laet et al. Longitudinal changes in ultrasound parameters of the calcaneus Osteoporosis International 7 1997 207-212
48. P. Hadji O. Hars M. Schuler et al. Assessment by quantitative ultrasonometry of the effects of hormon ereplacement therapy on bone mass American Journal of Obstetrics and Gynecology 182 2000 529-534
49. S. Gonnelli C. Cepollaro A. Montagnani et al. Heel ultrasonography in monitoring alendronate therapy: A four-year longitudinal study Osteoporosis International 13 2002 415-421
50. A.M. Schott D. Hans P. Garnero et al. Age-related changes in os calcis ultrasonic indices: A 2 year prospective study Osteoporosis International 5 1995 478-483
51. P. Garnero O. Borel P.D. Delmas Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis Clinical Chemistry 47 2001 694-702
52. P. Qvist S. Christgau B.J. Pedersen et al. Circadian variation in the serum C-terminal telopeptide of type I collagen (serum CTX): Effects of gender, age, menopausal status, posture, daylight, serum cortisol and fasting Bone 31 2002 57-61
53. A. Blumsohn K. Herrington R.A. Hannon et al. The effect of calcium supplementation on the circadian rhythm of bone resorption Journal of Clinical Endocrinology and Metabolism 79 1994 730-735
54. P. Garnero E. Hausherr M.C. Chapuy et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study Journal of Bone and Mineral Research 11 1996 1531-1538
55. P. Garnero E. Sornay-Rendu B. Claustrat & P.D. Delmas Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study Journal of Bone and Mineral Research 15 2000 1526-1536
56. P. Garnero D. Mulleman F. Munoz et al. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study Journal of Bone and Mineral Research 18 2003 1789-1794
57. P. Garnero P. Dargent-Molina D. Hans et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study Osteoporosis International 8 1998 563-569
58. M.J. Seibel V. Naganathan I. Barton & A. Grauer Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate Journal of Bone and Mineral Research 19 2004 394-401
59. Pd. Delmas P. Chen D.A. Misurski et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover Journal of Bone and Mineral Research 19 2004 S44
60. P. Garnero W.J. shih E. Gineyts et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment Journal of Clinical Endocrinology and Metabolism 79 1994 1693-1700
61. R. Eastell I. Barton R.A. Hannon et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate Journal of Bone and Mineral Research 18 2003 1051-1056
62. F. Tremollieres J.M. Pouilles & C. Ribot Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women Osteoporosis International 12 2001 385-390
63. P.D. Delmas How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis Bone 27 2000 1-3
64. D.C. Bauer D.M. Black P. Garnero et al. Change in bone turnover and hip, non spine, and vertebral fracture in alendronate-treated women Journal of Bone and Mineral Research 19 2004 1250-1258
65. N.H. Bjarnason C. Christiansen S. Sarkar et al. 6 months changes in biochemical markers predict 3-year response in vertebral fracture rate in postmenopausal, osteoporotic women: Results from the MORE study Osteoporosis International 12 2001 922-930
66. J.A. Clowes N.F. Peel & R. Eastell The impact of monitoring on adherence and presistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial Journal of Clinical Endocrinology and Metabolism 89 2004 1117-1123
67. R.D. Chapurlat & S.R. Cummings Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness? Osteoporosis International 13 2002 738-744